Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
03
03
2022
accepted:
04
08
2022
entrez:
13
10
2022
pubmed:
14
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
The spectrum of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) comprises monophasic diseases such as acute disseminated encephalomyelitis (ADEM), optic neuritis (ON), and transverse myelitis and relapsing courses of these presentations. Persistently high MOG antibodies (MOG immunoglobulin G [IgG]) are found in patients with a relapsing disease course. Prognostic factors to determine the clinical course of children with a first MOGAD are still lacking. The objective of the study is to assess the clinical and laboratory prognostic parameters for a risk of relapse and the temporal dynamics of MOG-IgG titers in children with MOGAD in correlation with clinical presentation and disease course. In this prospective multicenter hospital-based study, children with a first demyelinating attack and complete data set comprising clinical and radiologic findings, MOG-IgG titer at onset, and clinical and serologic follow-up data were included. Serum samples were analyzed by live cell-based assay, and a titer level of ≥1:160 was classified as MOG-IgG-positive. One hundred sixteen children (f:m = 57:59) with MOGAD were included and initially diagnosed with ADEM (n = 59), unilateral ON (n = 12), bilateral ON (n = 16), myelitis (n = 6), neuromyelitis optica spectrum disorder (n = 8) or encephalitis (n = 6). The median follow-up time was 3 years in monophasic and 5 years in relapsing patients. There was no significant association between disease course and MOG-IgG titers at onset, sex, age at presentation, or clinical phenotype. Seroconversion to MOG-IgG-negative within 2 years of the initial event showed a significant risk reduction for a relapsing disease course. Forty-two/one hundred sixteen patients (monophasic n = 26, relapsing n = 16) had serial MOG-IgG testing in years 1 and 2 after the initial event. In contrast to relapsing patients, monophasic patients showed a significant decrease of MOG-IgG titers during the first and second years, often with seroconversion to negative titers. During the follow-up, MOG-IgG titers were persistently higher in relapsing than in monophasic patients. Decrease in MOG-IgG of ≥3 dilution steps after the first and second years was shown to be associated with a decreased risk of relapses. In our cohort, no patient experienced a relapse after seroconversion to MOG-IgG-negative. In this study, patients with declining MOG-IgG titers, particularly those with seroconversion to MOG-IgG-negative, are shown to have a significantly reduced relapse risk.
Sections du résumé
BACKGROUND AND OBJECTIVE
The spectrum of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) comprises monophasic diseases such as acute disseminated encephalomyelitis (ADEM), optic neuritis (ON), and transverse myelitis and relapsing courses of these presentations. Persistently high MOG antibodies (MOG immunoglobulin G [IgG]) are found in patients with a relapsing disease course. Prognostic factors to determine the clinical course of children with a first MOGAD are still lacking. The objective of the study is to assess the clinical and laboratory prognostic parameters for a risk of relapse and the temporal dynamics of MOG-IgG titers in children with MOGAD in correlation with clinical presentation and disease course.
METHODS
In this prospective multicenter hospital-based study, children with a first demyelinating attack and complete data set comprising clinical and radiologic findings, MOG-IgG titer at onset, and clinical and serologic follow-up data were included. Serum samples were analyzed by live cell-based assay, and a titer level of ≥1:160 was classified as MOG-IgG-positive.
RESULTS
One hundred sixteen children (f:m = 57:59) with MOGAD were included and initially diagnosed with ADEM (n = 59), unilateral ON (n = 12), bilateral ON (n = 16), myelitis (n = 6), neuromyelitis optica spectrum disorder (n = 8) or encephalitis (n = 6). The median follow-up time was 3 years in monophasic and 5 years in relapsing patients. There was no significant association between disease course and MOG-IgG titers at onset, sex, age at presentation, or clinical phenotype. Seroconversion to MOG-IgG-negative within 2 years of the initial event showed a significant risk reduction for a relapsing disease course. Forty-two/one hundred sixteen patients (monophasic n = 26, relapsing n = 16) had serial MOG-IgG testing in years 1 and 2 after the initial event. In contrast to relapsing patients, monophasic patients showed a significant decrease of MOG-IgG titers during the first and second years, often with seroconversion to negative titers. During the follow-up, MOG-IgG titers were persistently higher in relapsing than in monophasic patients. Decrease in MOG-IgG of ≥3 dilution steps after the first and second years was shown to be associated with a decreased risk of relapses. In our cohort, no patient experienced a relapse after seroconversion to MOG-IgG-negative.
DISCUSSION
In this study, patients with declining MOG-IgG titers, particularly those with seroconversion to MOG-IgG-negative, are shown to have a significantly reduced relapse risk.
Identifiants
pubmed: 36229191
pii: 9/6/e200035
doi: 10.1212/NXI.0000000000200035
pmc: PMC9562044
pii:
doi:
Substances chimiques
Immunoglobulin G
0
Myelin-Oligodendrocyte Glycoprotein
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Clin Immunol. 2011 Mar;138(3):247-54
pubmed: 21169067
Neurology. 2011 Aug 9;77(6):580-8
pubmed: 21795651
J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):265-72
pubmed: 25121570
Ann Neurol. 2021 Jan;89(1):30-41
pubmed: 32959427
Acta Neuropathol Commun. 2019 Sep 3;7(1):145
pubmed: 31481127
Neurol Neuroimmunol Neuroinflamm. 2014 May 22;1(1):e12
pubmed: 25340056
Neurol Neuroimmunol Neuroinflamm. 2015 Mar 12;2(2):e81
pubmed: 25798445
Neurology. 2017 Aug 29;89(9):900-908
pubmed: 28768844
JAMA Neurol. 2020 Jan 1;77(1):82-93
pubmed: 31545352
J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):897-905
pubmed: 26645082
Mult Scler. 2013 Sep;19(10):1261-7
pubmed: 23572237
Eur J Paediatr Neurol. 2020 Nov;29:2-13
pubmed: 33162302
Mult Scler. 2013 Jun;19(7):941-6
pubmed: 23128668
Lancet Neurol. 2020 Mar;19(3):234-246
pubmed: 32057303
Neurol Neuroimmunol Neuroinflamm. 2020 May 1;7(4):
pubmed: 32358225
Mult Scler. 2019 Jun;25(7):927-936
pubmed: 30945587
Neurol Neuroimmunol Neuroinflamm. 2020 Feb 5;7(2):
pubmed: 32024795
J Neuroinflammation. 2011 Dec 28;8:184
pubmed: 22204662
Eur J Paediatr Neurol. 2020 Nov;29:41-53
pubmed: 33176999
Neurotherapeutics. 2019 Jul;16(3):828-837
pubmed: 30868469
BMJ Open. 2021 Nov 30;11(11):e055392
pubmed: 34848526
Eur J Paediatr Neurol. 2020 Jul;27:86-93
pubmed: 32327391
JAMA Neurol. 2021 Jun 1;78(6):741-746
pubmed: 33900394
Mult Scler. 2016 Dec;22(14):1821-1829
pubmed: 26869530
Mult Scler. 2016 Feb;22(2):174-84
pubmed: 26041801
J Neuroinflammation. 2015 Mar 08;12:46
pubmed: 25889963
Semin Vet Med Surg Small Anim. 1997 Aug;12(3):170-7
pubmed: 9283242
J Neuroinflammation. 2016 Sep 27;13(1):280
pubmed: 27793206
J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127-137
pubmed: 29142145